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ABSTRACT
Scalp psoriasis with alopecia is a rare cutaneous
reaction to tumor necrosis factor alpha
antagonists. This reaction often reverses with
discontinuation of the offending drug and
initiation of topical treatments; however,
irreversible hair loss may occur if a scarring
alopecia develops. We describe a woman with
Crohn’s disease who developed scalp psoriasis
and alopecia secondary to infliximab. She had a
remarkable recovery after discontinuation of
infliximab and treatment with oral minocycline
and topical therapy: mineral oil under
occlusion, betamethasone lotion, and
sequential coal tar, salicylic acid, and
ketoconazole shampoos each day. The
patient’s alopecia completely resolved within 4
months of initiating this treatment regimen. In
summary, early diagnosis of alopecia secondary
to tumor necrosis factor alpha antagonist
therapy is crucial in preventing diffuse
alopecia and scalp psoriasis. In addition to
discontinuing the offending agent, initiating
aggressive adjuvant treatment with an oral
antibiotic, topical therapies, or both, should
be considered to reverse tumor necrosis factor
alpha antagonist-induced alopecia and/or scalp
psoriasis.
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INTRODUCTION
Tumor necrosis factor alpha antagonists can
treat a variety of rheumatic diseases including
ankylosing spondylitis, inflammatory bowel
diseases, and psoriasis [1]. Yet, these drugs
may paradoxically cause psoriasis or scalp
alopecia, or both. Tumor necrosis factor alpha
inhibitor-induced psoriasis is rare with an
incidence of 1.04–3.0 cases per 1000
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person-years [2]. This may result in skin or scalp
lesions. Rarely, a scarring alopecia may develop;
this reaction has only been described twice in
the literature—both in patients being treated
with adalimumab [3, 4]. We report a patient
with Crohn’s disease being treated with
infliximab who developed alopecia and scalp
psoriasis. The patient’s scalp remarkably
improved after discontinuation of infliximab
and the initiation of oral and topical therapies.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from the
patient for being included in the study.
CASE REPORT
A 23-year-old female with a history of Crohn’s
disease had previously presented to another
dermatologist for evaluation of alopecia. She
had been treated with azathioprine, and her
hair loss began 8 months after adding
infliximab therapy.
At that time, her scalp examination showed
diffuse alopecia and an erythematous plaque
with superficial scaling (Fig. 1). A punch biopsy
of the scalp was performed, and histopathologic
examination revealed chronic folliculitis and
perifolliculitis with dermal scarring and naked
hair shafts in the dermal stroma. These
histopathologic findings were consistent with
a diagnosis of folliculitis decalvans.
Infliximab infusions were discontinued, and
the patient was prescribed oral minocycline
(100 mg twice daily) to treat her folliculitis
decalvans. During the subsequent month, her
alopecia progressed, and she developed pruritic
lesions that covered her scalp. She presented to
us for a second opinion.
Her scalp examination now demonstrated
psoriasiform changes characterized by
well-defined erythematous plaques with an
overlying white silvery scale (Fig. 2). The
diagnosis of alopecia and scalp psoriasis
secondary to infliximab treatment was
suspected. Severe seborrheic dermatitis and/or
scalp infection was also included in the
differential diagnosis.
Initially, adjuvant topical interventions were
initiated. The patient applied betamethasone
lotion twice daily. In addition, mineral oil was
covered with a shower cap on the scalp
overnight. Each morning, either 5% coal tar,
2% ketoconazole, or 6% salicylic acid shampoo
was used to wash the scalp. The twice daily oral
minocycline was maintained, and a bacterial
culture of her scalp was performed.
Two additional bacterial cultures of her scalp
(monthly, over the subsequent months) were
performed to assess for the possibility of
associated infection; the patient continued the
Fig. 1 The scalp of a 23-year-old female who had been
receiving inﬂiximab to treat Crohn’s disease. An erythe-
matous plaque with overlying scale and diffuse alopecia is
noted
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oral minocycline therapy during this time. The
scalp bacterial cultures grew Acinetobacter
species, Acinetobacter baumanii, and
Acinetobacter radioresistens, respectively—each
of the organisms was susceptible to
minocycline. However, since the variants of
Acinetobacter continued to persist while she
received minocycline treatment, consultation
with an infectious disease specialist determined
that the isolated bacteria were commensal
species, and the oral antibiotic was
discontinued.
The patient’s alopecia and scalp psoriasis
both remarkably improved. Indeed, at her
4-month follow-up visit there were no scalp
scales and all of her hair had returned (Fig. 3).
Her topical scalp therapies were tapered and
subsequently discontinued. Neither her
alopecia nor scalp psoriasis recurred.
Ustekinumab was initiated to treat her
Crohn’s disease, and her inflammatory bowel
disease remains well controlled. In addition, she
has not developed either alopecia or scalp
psoriasis.
DISCUSSION
Anti-tumor necrosis factor alpha therapy may
be associated with alopecia, dermatitis,
infections, and psoriasis [1, 5]. Rheumatoid
arthritis is the most common underlying
illness, present in 46.0% (80/174) of patients,
associated with tumor necrosis factor alpha
antagonist-induced psoriasis [6]. This adverse
event usually manifests as a pustular eruption
on the palms of the hands and/or soles of the
feet (palmoplantar pustulosis). Palmoplantar
pustulosis is very rare within the general
population, so its discovery should prompt
investigation of the patient’s medications [6].
A retrospective analysis found 29.4% (203/
690) of Crohn’s patients who began tumor
necrosis factor alpha-antagonist therapy
developed various skin lesions [7]. Psoriasis
composes 22.9% (8/35) of anti-tumor necrosis
factor alpha-related cutaneous reactions with a
prevalence of 1.5–5% in these patients [1, 8]. It
may occur days to years after beginning
treatment, and women from 40 to 50 years old
are at the highest risk of developing a
psoriasiform reaction [6, 8].
Scalp psoriasis is usually characterized by
discrete psoriatic plaques on the scalp, with or
without alopecia, that may itch intensely
[3, 4, 9, 10]. In contrast to palmoplantar
pustulosis (where rheumatoid arthritis is the
most common underlying disease), Crohn’s
disease usually underlies the very rare
Fig. 2 The patient’s scalp 1 month after beginning
minocycline therapy and discontinuing inﬂiximab. Her
alopecia persists; in addition, psoriasiform changes charac-
terized by a well-deﬁned erythematous plaque with an
overlying white silvery scale are present
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manifestation of tumor necrosis factor alpha
antagonist-induced scalp psoriasis. A case series
and literature review reported 15 such
individuals; 80% (12/15) of the patients had a
history of Crohn’s disease [10].
The differential diagnosis of tumor necrosis
factor alpha antagonist-induced hair loss
includes alopecia areata, pityriasis amiantacea,
psoriasis, and tinea capitis [11]. A retrospective
review of drug reactions found infliximab to be
the most common tumor necrosis factor
alpha-antagonist to cause alopecia (18/52
cases, 35%) [12]. This study also noted that
tumor necrosis factor alpha-antagonist
exposure was three times more likely
(reporting odds ratio = 3.0) in patients with
alopecia than other adverse drug reactions.
Another study found the average duration of
exposure to tumor necrosis factor
alpha-antagonists before the development of
alopecia areata to be 22.5 months [13]. This
prospective report found 76% of alopecia areata
cases to partially or completely resolve over a
mean of 5 months with no difference in
alopecia areata resolution between those that
discontinued and continued tumor necrosis
factor alpha-antagonist treatment.
Biopsy and histologic examination of the
alopecia may be useful in establishing the
diagnosis. In addition to classic psoriasiform
epidermal changes of idiopathic psoriasis, the
histopathology of tumor necrosis factor alpha
antagonist-induced psoriasis can also show
alterations similar to alopecia areata. These
may include hair follicle miniaturization,
increased catagen and telogen hairs, and
peribulbar lymphocytic infiltrate occupying all
levels of the terminal hair structure [11].
The histology of our patient’s scalp alopecia
(consisting of chronic folliculitis and
perifolliculitis, dermal scarring, and naked hair
shafts in the dermal stroma) was consistent with
the diagnosis of folliculitis decalvans—a type of
scarring alopecia that may present with
pustules, inflammatory papules, tunneling
hairs, and permanent hair loss [14]. The
dramatic response to our intervention with
complete regrowth of hair was unexpected
Fig. 3 Distant (a) and closer (b) images of the patient’s hair and scalp. The patient’s alopecia had completely resolved at her
4-month follow-up visit (a). Small areas with shorter hair, representing new hair growth, are seen (b)
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based on this presumed diagnosis. Furthermore,
infliximab has been used to treat folliculitis
decalvans, so its discontinuation would not be
expected to cure the disease [15].
Therefore, in our patient, it is possible that a
reversible scarring alopecia resembling
folliculitis decalvans concurrently occurred
with psoriasis scalp. Alternatively, it is possible
that the biopsy was obtained from a
non-representative area of the scalp, and the
true diagnosis was tumor necrosis factor
alpha-induced psoriasis complicated by an
overlying cellulitis. Minocycline was initially
selected as a first-line therapy for folliculitis
decalvans [16]. However, it likely aided in
resolving an overlying cellulitis or
impetiginization and may have helped to
decrease local dermal inflammation.
Infliximab may be used to treat psoriasis. Yet,
paradoxically, infliximab is implicated in the
development of this very disease especially in
patients with Crohn’s disease [6, 15, 17]. In vitro
tumor necrosis factor alpha significantly inhibits
hair growth [18]. However, tumor necrosis factor
alpha antagonists may cause hair loss instead of
inhibiting it.
A possible mechanism for tumor necrosis
factor alpha antagonist-induced psoriasis
involves dermal plasmocytoid dendritic cells.
These cells produce interferon-alpha, an
important cytokine in the pathogenesis of
psoriasis, and may be induced by tumor
necrosis factor alpha antagonists. In turn, this
would cause the migration of T cells to the skin
via interleukin-15 and a psoriasiform reaction
[8]. It is possible that alopecia and psoriasis
occurred in the patient secondary to the
anti-tumor necrosis factor alpha agent as these
diseases seem to be related to different aspects
of the medication.
In tumor necrosis factor alpha
antagonist-induced psoriasis, the offending
drug should be discontinued and topical
corticosteroid therapy should be initiated. In
one review, 82% (50/61) of patients experienced
complete resolution of their drug-induced
psoriasis after discontinuing the offending
tumor necrosis factor alpha antagonist.
However, many patients cannot discontinue
their tumor necrosis factor alpha antagonist;
most of these patients experience complete
(50%, 53/107) or partial (49%, 52/107)
resolution of their drug-induced psoriasis.
Alternatively, a different tumor necrosis factor
alpha antagonist may be attempted, and 52%
(13/25) of patients had no reoccurrence of their
lesions following this change [19].
If scalp psoriasis continues without
treatment, permanent alopecia may result [10].
Topical corticosteroids, such as betamethasone
0.05% lotion and a daily shampoo with
alternating agents (5% coal tar, 2%
ketoconazole, and 6% salicylic acid) that are
applied to the scalp can be used in the
treatment of scalp psoriasis [11]. In addition,
mineral oil followed by occlusion with a shower
cap can promote the desquamation of the
plaques. Our patient’s scalp was very sensitive;
therefore, we used a corticosteroid in a lotion
instead of a solution.
A recent report described the efficacy of
using ustekinumab, an anti-interleukin-12/-23
monoclonal antibody, to treat concurrent
inflammatory bowel disease and plaque
psoriasis [9]. Our patient was also placed on
ustekinumab to manage her Crohn’s disease.
However, her scalp condition had significantly
improved prior to beginning the treatment. She
is doing well on this therapy and has had no
recurrence of her alopecia or scalp psoriasis.
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CONCLUSION
Tumor necrosis factor alpha antagonists may
cause a variety of cutaneous adverse events. An
idiosyncratic reaction of these drugs is the
development of psoriasis—a condition they are
used to treat. Although this reaction typically
manifests as palmoplantar pustulosis, scalp
psoriasis may also occur. Tumor necrosis factor
alpha-induced scalp psoriasis appears to manifest
most frequently in patients with Crohn’s disease.
Alopecia and possibly folliculitis decalvans may
also be a sequella of this drug reaction. Thus, in
addition to adjuvant measures to resolve the
alopecia, psoriasis, or both—such as topical
corticosteroids and therapeutic shampoos—
discontinuation of the offending drug and
initiation of a different tumor necrosis factor
alpha antagonist or immunotherapy, such as
ustekinumab, is recommended. Minocycline
treatment likely had a favorable influence on
our patient’s alopecia and scalp psoriasis—
perhaps secondary to the resolution of an
overlying cellulitis or impetiginization, or as a
result of its anti-inflammatory activity.
In summary, accurate diagnosis and
treatment of infliximab-induced alopecia and
scalp psoriasis resulted in an excellent clinical
response for our patient with complete regrowth
of her scalp hair. She was subsequently placed on
an alternate inflammatory bowel disease
therapy. Alopecia or psoriasis, or both, in a
patient receiving infliximab, should prompt
immediate discontinuation of the drug to
prevent progression of the adverse cutaneous
drug reaction.
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